Abu Dhabi Implements Breakthrough Gene Therapy for Spinal Muscular Atrophy
Introduction of ITVISMA in Abu Dhabi
Abu Dhabi has taken a significant step in advancing medical treatments by becoming one of the first cities globally to introduce ITVISMA, a pioneering gene therapy developed to address spinal muscular atrophy (SMA). This innovative treatment, created by Novartis, is designed for patients aged two years and older who carry a confirmed SMN1 gene mutation.
Function and Benefits of ITVISMA
ITVISMA represents a one-time gene therapy that directly targets the underlying genetic cause of SMA, effectively replacing the missing SMN1 gene. This mechanism is designed to enhance motor function, thereby decreasing the reliance on ongoing therapies that are commonly necessary with other treatment options. The introduction of this therapy underscores a transformative move towards precise and personalized medicine for individuals affected by this condition.
Administration at Sheikh Khalifa Medical City
The successful administration of ITVISMA took place at Sheikh Khalifa Medical City (SKMC), a facility under the SEHA umbrella and a subsidiary of PureHealth. This milestone was achieved under the supervision of the Department of Health – Abu Dhabi (DoH), showcasing the collaborative efforts within Abu Dhabi’s healthcare system to implement cutting-edge treatments.
A Global Milestone in Healthcare
With the administration of ITVISMA, Abu Dhabi has solidified its position as the first city worldwide to provide this advanced treatment for SMA. This accomplishment enhances the emirate’s reputation as a leading global healthcare destination while demonstrating its commitment to innovative patient care through advancements in genomics and precision medicine.
Regulatory Endorsements
The groundbreaking therapy received accelerated approval in the UAE on November 25, shortly after its endorsement by the US Food & Drug Administration (FDA). This rapid approval has established the UAE as one of the frontrunners globally in adopting this revolutionary treatment for SMA, trailing only the USA in its swift regulatory processes.
Research and Study Validation
Novartis has indicated that the approval of ITVISMA is grounded in substantial data derived from the registrational Phase III STEER study. The findings were further supported by the open-label Phase IIIb STRENGTH study. The results highlighted statistically significant improvements in motor function, demonstrating stabilisation of motor abilities that are typically not seen in the natural progression of the disease. These effects were noted to be sustained over a 52-week follow-up period.
Safety Profile Observations
The safety profile of ITVISMA was also thoroughly evaluated, with adverse events being consistent across both studies. Common adverse events noted in the STEER study included upper respiratory tract infections and pyrexia, while the STRENGTH study reported a prevalence of common cold, pyrexia, and vomiting.
Statements from Health Officials
Dr. Noura Khamis Al Ghaithi, Under-Secretary of DoH, remarked, “This milestone reflects Abu Dhabi’s commitment to delivering world-class care and strengthening its position as a global leader in healthcare driven by genomics and precision medicine.” Her statement emphasized the pride associated with being among the first to provide such an innovative treatment, further solidifying Abu Dhabi’s leadership in advanced healthcare.
Commitment from Healthcare Leaders
Bader Al Qubaisi, CEO of SKMC, noted the achievement of delivering the world’s first ITVISMA treatment as a reflection of Abu Dhabi’s robust and integrated healthcare system. He acknowledged the efforts of the DoH and PureHealth in facilitating smooth pathways for care and collaboration with key partners, enabling the safe and efficient provision of this transformative therapy to patients in need.
Mohamed Ezz Eldin, head of the GCC Cluster at Novartis, expressed pride in facilitating accelerated access to breakthrough therapies like ITVISMA. He underscored the importance of collaboration with the Department of Health – Abu Dhabi and SKMC in enhancing the capital’s role as a regional and global reference for advanced neuromuscular care.
Importance of Advanced Treatment Options
The introduction of ITVISMA represents a crucial advance in the healthcare landscape of Abu Dhabi, marking a pivotal moment in the ongoing fight against spinal muscular atrophy. The ability to provide such innovative treatments echoes the emirate’s broader vision for integrating advanced healthcare technologies into patient care strategies.
This major development not only illustrates the capabilities of Abu Dhabi’s healthcare industry but also highlights a significant leap towards enhancing the quality of life for individuals impacted by SMA. The efforts involved in this process showcase a steadfast commitment to ensuring that patients have access to the most advanced treatments available today.
Published on 1767012880 • Category: Healthcare,Abu Dhabi,Department of Health – Abu Dhabi,healthcare industry